# Amatuximab for High Mesothelin Cancers

> **NCT01413451** · EARLY_PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 7 (actual)

## Conditions studied

- Carcinoma, Pancreatic Ductal
- Mesothelioma
- Ovarian Neoplasms
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Amatuximab (MORab-009)

## Key facts

- **NCT ID:** NCT01413451
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07-12
- **Primary completion:** 2013-11-15
- **Final completion:** 2013-11-15
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01413451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01413451, "Amatuximab for High Mesothelin Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01413451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*